Roughly 14 million US adults are diagnosed with COPD, but the blood eosinophil count now decides who reaches a biologic.

COPD remains one of the largest chronic-disease populations in the United States and a leading cause of death, accounting for the majority of chronic lower respiratory disease deaths and ranking as the fourth leading US cause of death in 2019 per CDC MMWR data. Diagnosed prevalence, though, understates the true burden. National survey data show a substantial fraction of at-risk adults have never received a breathing test, leaving a large undiagnosed pool that never enters the treatment pathway at all.

Diagnosis is spirometric, a post-bronchodilator FEV1/FVC ratio below 0.70, and management is now staged by the GOLD A-E system, which in its 2023 revision replaced the old C and D groups with a single exacerbator group, E. The pivotal shift for commercial strategy is biological: the blood eosinophil count, at or above 300 cells per microliter, is the gate that determines whether an exacerbating patient can reach the first COPD biologic. That single lab value converts a symptom-and-history pathway into a biomarker-stratified one.

A single blood test now gates access to the newest COPD therapy.

Five questions this report answers:

Q1 - How big is the biologic-eligible slice once eosinophil 300+ is layered onto treatment failures?

Q2 - Where does the undiagnosed COPD pool sit in the pathway, and what unlocks it?

Q3 - How does the 2023 GOLD A-E reclassification change escalation to add-on therapy?

Q4 - What is the US COPD epidemiology and treatment pathway, and where does the eosinophil biomarker fit?

Q5 - Why does COPD remain a leading cause of death despite being underdiagnosed nationally?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#COPD #Biologics #Eosinophil #RespiratoryHealth #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/copd/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/